Biogen to participate in development of Genentech’s mosunetuzumab
koto_feja/E+ via Getty Images


Biogen (NASDAQ:BIIB) has exercised its option to participate in the development and commercialization of mosunetuzumab.
The company will pay a $30M one-time option fee to Roche (OTCQX:RHHBY) unit, Genentech, as part of the companiesâ long-standing collaboration on antibodies targeting CD20; and will also pay for a portion of the mosunetuzumab development expenses incurred during 2021.

BIIB will have joint decision-making rights related to development and commercialization of mosunetuzumab and Genentech will continue to lead the strategy and implementation of the program.
Biogen will share in operating profits and losses of mosunetuzumab in U.S. in the low to mid 30% range and is eligible to receive low single-digit royalties on sales outside U.S.
Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development for the treatment of people with B-cell non-Hodgkinâs lymphoma, including follicular lymphoma and diffuse large B-cell lymphoma.